Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Emerging role of orexin antagonists in insomnia therapeutics: An update on SORAs and DORAs
Anil Kumar, Priyanka Chanana, Supriti Choudhary
Pharmacological Reports (2015) Vol. 68, Iss. 2, pp. 231-242
Closed Access | Times Cited: 35

Showing 1-25 of 35 citing articles:

Lemborexant, A Dual Orexin Receptor Antagonist (DORA) for the Treatment of Insomnia Disorder: Results From a Bayesian, Adaptive, Randomized, Double-Blind, Placebo-Controlled Study
Patricia Murphy, Margaret Moline, David Mayleben, et al.
Journal of Clinical Sleep Medicine (2017) Vol. 13, Iss. 11, pp. 1289-1299
Open Access | Times Cited: 298
Arousal and sleep circuits
Barbara E. Jones
Neuropsychopharmacology (2019) Vol. 45, Iss. 1, pp. 6-20
Open Access | Times Cited: 189
Targeting Orexin Receptors for the Treatment of Insomnia: From Physiological Mechanisms to Current Clinical Evidence and Recommendations
Maria P. Mogavero, Alessandro Silvani, Giuseppe Lanza, et al.
Nature and Science of Sleep (2023) Vol. Volume 15, pp. 17-38
Open Access | Times Cited: 23
Genomics and Proteomics Studies of Zolpidem, Necopidem, Alpidem, Saripidem, Miroprofen, Zolimidine, Olprinone and Abafungin as Antitumor, Peptide Antibiotics, Antiviral and Central Nervous System (CNS) Drugs
Ava Heidari
Journal of Data Mining in Genomics & Proteomics (2016) Vol. 7, Iss. 3
Open Access | Times Cited: 85
An Update on Dual Orexin Receptor Antagonists and Their Potential Role in Insomnia Therapeutics
Kayla Janto, J. Roxanne Prichard, Snigdha Pusalavidyasagar
Journal of Clinical Sleep Medicine (2018) Vol. 14, Iss. 08, pp. 1399-1408
Open Access | Times Cited: 81
Practitioner Review: Treatment of chronic insomnia in children and adolescents with neurodevelopmental disabilities
Oliviero Bruni, Marco Angriman, Fabrizio Calisti, et al.
Journal of Child Psychology and Psychiatry (2017) Vol. 59, Iss. 5, pp. 489-508
Open Access | Times Cited: 77
Pharmacotherapeutic management of sleep disorders in children with neurodevelopmental disorders
Oliviero Bruni, Marco Angriman, Maria Grazia Melegari, et al.
Expert Opinion on Pharmacotherapy (2019) Vol. 20, Iss. 18, pp. 2257-2271
Closed Access | Times Cited: 62
Efficacy of Lemborexant in Adults ≥ 65 Years of Age with Insomnia Disorder
Valerie Arnold, Sonia Ancoli‐Israel, Thien Thanh Dang‐Vu, et al.
Neurology and Therapy (2024) Vol. 13, Iss. 4, pp. 1081-1098
Open Access | Times Cited: 6
Microglia in Alzheimer’s Disease: An Unprecedented Opportunity as Prospective Drug Target
Bhargavi Kulkarni, Natália Martins, Dileep Kumar
Molecular Neurobiology (2022) Vol. 59, Iss. 5, pp. 2678-2693
Closed Access | Times Cited: 25
Clinical usefulness of dual orexin receptor antagonism beyond insomnia: Neurological and psychiatric comorbidities
Matteo Carpi, Laura Palagini, Mariana Fernandes, et al.
Neuropharmacology (2023) Vol. 245, pp. 109815-109815
Open Access | Times Cited: 15
Orexin dual receptor antagonists, zolpidem, zopiclone, eszopiclone, and cognitive research: A comprehensive dose-response meta-analysis
Mengzhen Zhou, Jiyou Tang, Shasha Li, et al.
Frontiers in Human Neuroscience (2023) Vol. 16
Open Access | Times Cited: 11
Targeting sleep and the circadian system as a novel treatment strategy for Parkinson’s disease
Beatrix Feigl, Simon J.G. Lewis, Oliver Rawashdeh
Journal of Neurology (2023) Vol. 271, Iss. 3, pp. 1483-1491
Open Access | Times Cited: 8
UPLC-MS/MS Based Identification and Quantification of a Novel Dual Orexin Receptor Antagonist in Plasma Samples by Validated SWGTOX Guidelines
Muzaffar Iqbal, Abdullah K. Alshememry, Faisal Imam, et al.
Toxics (2023) Vol. 11, Iss. 2, pp. 109-109
Open Access | Times Cited: 7
A Simple, Sensitive, and Greener HPLC-DAD Method for the Simultaneous Analysis of Two Novel Orexin Receptor Antagonists
Muzaffar Iqbal, Nazrul Haq, Mohd Abul Kalam, et al.
ACS Omega (2024) Vol. 9, Iss. 21, pp. 23101-23110
Open Access | Times Cited: 2
Multiple daytime administration of the selective orexin-2 receptor antagonist JNJ-42847922 induces somnolence in healthy subjects without residual central effects
Peter van der Ark, Georg Golor, Luc Van Nueten, et al.
Journal of Psychopharmacology (2018) Vol. 32, Iss. 12, pp. 1330-1340
Closed Access | Times Cited: 16
Improvement in fatigue and sleep measures with the dual orexin receptor antagonist lemborexant in adults with insomnia disorder
Craig Chepke, Rakesh Jain, Russell Rosenberg, et al.
Postgraduate Medicine (2022) Vol. 134, Iss. 3, pp. 316-325
Open Access | Times Cited: 9
Contrasting the validation parameters and greenness of normal-phase and reverse-phase stability-indicating HPTLC methods for lemborexant analysis
Tariq M. Aljarba, Faiyaz Shakeel, Sultan Alshehri, et al.
Arabian Journal of Chemistry (2024) Vol. 17, Iss. 7, pp. 105837-105837
Open Access | Times Cited: 1
Review of the Efficacy and Safety of Lemborexant, a Dual Receptor Orexin Antagonist (DORA), in the Treatment of Adults With Insomnia Disorder
Kristin Waters
Annals of Pharmacotherapy (2021) Vol. 56, Iss. 2, pp. 213-221
Closed Access | Times Cited: 11
Medical Professionals and Pharmacological Intervention for the Treatment of Insomnia: A Cross-Sectional Study
Antonios Liaskopoulos, Vasileios Kakouris, Nikolaos Liaskopoulos, et al.
Sleep Science (2024)
Open Access | Times Cited: 1
Neurophysiology and Treatment of Disorders of Consciousness Induced by Traumatic Brain Injury: Orexin Signaling as a Potential Therapeutic Target
Huiling Tang, Qiumei Zhu, Wei Li, et al.
Current Pharmaceutical Design (2019) Vol. 25, Iss. 39, pp. 4208-4220
Closed Access | Times Cited: 11
Oxadiazole Derivatives as Dual Orexin Receptor Antagonists: Synthesis, Structure–Activity Relationships, and Sleep‐Promoting Properties in Rats
Christine Brotschi, Catherine Roch, John Gatfield, et al.
ChemMedChem (2019) Vol. 14, Iss. 13, pp. 1257-1270
Closed Access | Times Cited: 10
Investigation of orexin-2 selective receptor antagonists: Structural modifications resulting in dual orexin receptor antagonists
Jason W. Skudlarek, Christina N. DiMarco, Kerim Babaoglu, et al.
Bioorganic & Medicinal Chemistry Letters (2017) Vol. 27, Iss. 6, pp. 1364-1370
Closed Access | Times Cited: 8
Antagonists of Orexin Receptors as Potential Treatment of Sleep Disorders, Obesity, Eating Disorders, and Other Neurological and Psychiatric Disorders
Ahmed F. Abdel‐Magid
ACS Medicinal Chemistry Letters (2016) Vol. 7, Iss. 10, pp. 876-877
Open Access | Times Cited: 7
From orexin receptor agonist YNT-185 to novel antagonists with drug-like properties for the treatment of insomnia
Eva Mezeiová, Jana Janočková, Jan Konečný, et al.
Bioorganic Chemistry (2020) Vol. 103, pp. 104179-104179
Closed Access | Times Cited: 6
An alerting structure: human orexin receptor 1
Daniel Wacker, Bryan L. Roth
Nature Structural & Molecular Biology (2016) Vol. 23, Iss. 4, pp. 265-266
Open Access | Times Cited: 4
Page 1 - Next Page

Scroll to top